Ignacio Diane N, Mason Kimberly D, Hackett-Morton Ezra C, Albanese Christopher, Ringer Lymor, Wagner William D, Wang Paul C, Carducci Michael A, Kachhap Sushant K, Paller Channing J, Mendonca Janet, Li-Ying Chan Leo, Lin Bo, Hartle Diane K, Green Jeffrey E, Brown Collis A, Hudson Tamaro S
Howard University Cancer Center, Washington DC 20060, United States.
The University of the West Indies, St. Augustine Campus, Faculty of Medical Sciences, School of Pharmacy, Eric Williams Medical Sciences Complex, Champs Fleurs, Trinidad and Tobago.
Heliyon. 2019 Jan 16;5(1):e01128. doi: 10.1016/j.heliyon.2019.e01128. eCollection 2019 Jan.
Previously we demonstrated that muscadine grape skin extract (MSKE), a natural product, significantly inhibited androgen-responsive prostate cancer cell growth by inducing apoptosis through the targeting of survival pathways. However, the therapeutic effect of MSKE on more aggressive androgen-independent prostate cancer remains unknown. This study examined the effects of MSKE treatment in metastatic prostate cancer using complementary PC-3 cells and xenograft model. MSKE significantly inhibited PC-3 human prostate cancer cell tumor growth and . The growth-inhibitory effect of MSKE appeared to be through the induction of cell-cycle arrest. This induction was accompanied by a reduction in the protein expression of Hsp40 and cell-cycle regulation proteins, cyclin D1 and NF-kBp65. In addition, MSKE induced p21 expression independent of wild-type p53 induced protein expression. Moreover, we demonstrate that MSKE significantly inhibited cell migration in PC-3 prostate cancer cells. Overall, these results demonstrate that MSKE inhibits prostate tumor growth and migration, and induces cell-cycle arrest by targeting Hsp40 and proteins involved in cell-cycle regulation and proliferation. This suggests that MSKE may also be explored either as a neo-adjuvant or therapeutic for castration resistant prostate cancer.
此前我们证明,天然产物马斯卡丁葡萄皮提取物(MSKE)通过靶向生存途径诱导凋亡,显著抑制雄激素应答性前列腺癌细胞生长。然而,MSKE对更具侵袭性的雄激素非依赖性前列腺癌的治疗效果尚不清楚。本研究使用互补的PC-3细胞和异种移植模型,研究了MSKE治疗转移性前列腺癌的效果。MSKE显著抑制PC-3人前列腺癌细胞肿瘤生长。MSKE的生长抑制作用似乎是通过诱导细胞周期停滞实现的。这种诱导伴随着热休克蛋白40(Hsp40)以及细胞周期调节蛋白细胞周期蛋白D1和核因子κB p65(NF-kBp65)的蛋白表达降低。此外,MSKE诱导p21表达,且不依赖于野生型p53诱导的蛋白表达。此外,我们证明MSKE显著抑制PC-3前列腺癌细胞的细胞迁移。总体而言,这些结果表明,MSKE通过靶向Hsp40以及参与细胞周期调节和增殖的蛋白质,抑制前列腺肿瘤生长和迁移,并诱导细胞周期停滞。这表明,MSKE也可作为去势抵抗性前列腺癌的新辅助治疗或治疗药物进行探索。